The economics of screening first.
When computational screening costs near zero, every dollar of experimental budget goes further. Here is the business case.
When computational screening costs near zero, every dollar of experimental budget goes further. Here is the business case.
Most R&D teams screen late. Candidates are designed, synthesized, and tested before safety or property viability is checked computationally. The result is predictable: a significant fraction of experimental investment goes toward candidates that could have been flagged computationally months earlier.
Typical cost to advance one compound through preclinical
of clinical failures are ADMET-related (pharmacokinetics, toxicity)
Typical DFT campaign for 200–500 candidate compositions
HPC cluster costs for a mid-size computational materials group
Every late-stage failure represents not just the cost of the failed experiment, but the opportunity cost of all the work that led to it. Computational pre-screening eliminates the most obvious failures before any bench time is spent.
Full ADMET panel: solubility, permeability, CYP inhibition, hERG, hepatotoxicity.
DFT estimate assumes a 64-core HPC cluster running continuously. Experimental estimate assumes synthesis + assay for each compound.
Annual cost for a team of 10 scientists running routine screening campaigns.
| Cost element | DFT suite | ML platform | FluxMateria |
|---|---|---|---|
| Software license | $150K–300K (per-seat pricing, 10 users) |
$50K–150K (platform + API access) |
By quote |
| Compute infrastructure | $50K–200K (HPC cluster or cloud GPU) |
$10K–30K (inference compute) |
Scoped in the quote |
| Specialist FTEs | 1–3 dedicated (comp chem PhDs to run DFT) |
0.5–1 dedicated (ML engineer for retraining) |
0 (no specialist needed) |
| Model retraining / maintenance | N/A | $20K–50K/yr (data curation + retraining) |
N/A (no training data, no retraining) |
| Estimated annual total | $200K–500K+ | $80K–230K | By quote |
DFT suite costs based on published pricing for Schrödinger, BIOVIA, and VASP commercial licenses. ML platform costs based on typical SaaS pricing for cheminformatics platforms. All estimates are illustrative; actual costs vary by organization and usage.
One scientist with FluxMateria can do the screening work that previously required a computational chemistry team.
Any medicinal chemist, materials scientist, or bench researcher can run screenings directly. No computational chemistry expertise required.
Moving screening from the end of the pipeline to the beginning changes the economics of every downstream step.
Pre-screen eliminates candidates with ADMET liabilities before any bench work starts.
Screen the entire candidate space, not a curated subset. No promising candidates missed.
No retraining needed. New scaffolds, new compositions, new chemical spaces — all from day one.
The math
Use your synthesis and assay costs to estimate the value of avoiding follow-up on low-priority compounds. A focused pilot can help your team measure that value on an upcoming decision.
Traditional toolchains require separate licenses, separate infrastructure, and separate expertise for each domain.
| Capability | Traditional stack | FluxMateria |
|---|---|---|
| ADMET screening | Separate ML platform or vendor assays | Built-in (350 mol/sec) |
| Materials properties | VASP / Quantum ESPRESSO + HPC | Built-in (1,000+ materials) |
| Reaction mechanisms | Gaussian + specialist interpretation | Built-in (99.4% classification, 334/336 cases) |
| Spectroscopy | Separate spectroscopy suite | Built-in (IR, NMR, UV-Vis) |
| Synthesis planning | Separate retrosynthesis tool | Built-in (29 reaction types) |
| Target engagement | Separate docking / scoring platform | Built-in (91% MoA accuracy) |
Consolidating from 4–6 separate tools to one platform reduces license costs, integration effort, vendor management overhead, and the number of specialized FTEs required to operate the toolchain.
If you are building a business case for your procurement or budget committee, here are the points that matter:
The €5,000 pilot covers one workflow, one agreed dataset, and one upcoming R&D decision.
No HPC cluster, no GPU procurement, no IT setup. SaaS delivery with API access. Time to first result: same day.
We quote annual access for a defined team and recurring workflow. If you’re considering annual access, we’ll share an indicative quote before you sign the pilot agreement.
A typical pilot delivers property predictions or a ranked shortlist, a comparison with your current method where available, and a technical readout.
Deterministic outputs, append-only audit logs, full provenance tracking. Every result is traceable and reproducible for regulatory and compliance review.
Start with a free blind benchmark if your team qualifies, or scope a focused pilot for an upcoming decision.